 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- | SIM0235 / Simcere
Enrollment change, Metastases: A Phase I Trial of SIM1811-03 in Subjects With Advanced Tumors (clinicaltrials.gov) - Sep 21, 2023
P1, N=255, Recruiting, Sponsor: Jiangsu Simcere Biologics Co., Ltd
N=120 --> 255
- SIM0235 / Simcere
SIM1811-03 (SIM0235), an anti-tumor necrosis factor receptor-2 (TNFR2) monoclonal antibody, in patients with advanced solid tumor and/or cutaneous T cell lymphomas (CTCL): Preliminary results from an on-going first-in-human phase I trial in China () - Jul 27, 2023 - Abstract #ESMO2023ESMO_2269;
P1
The preliminary PK and PD results support every 3-week dosing at 40mg/kg as the recommended dose for expansion. The clinical development of SIM1811-03 in combination with immunotherapy is planned.
- ||| SIM0235 / Simcere
New P1 trial, Metastases: A Phase I Trial of SIM1811-03 in Subjects With Advanced Tumors (clinicaltrials.gov) - Mar 23, 2023
P1, N=120, Recruiting, Sponsor: Jiangsu Simcere Pharmaceutical Co., Ltd.
- ||| SIM0235 / Simcere
New P1 trial, Metastases: A Phase I Trial of SIM1811-03 in Subjects With Advanced Solid Tumors and Cutaneous T-cell Lymphoma (clinicaltrials.gov) - Oct 6, 2022
P1, N=100, Recruiting, Sponsor: Jiangsu Simcere Pharmaceutical Co., Ltd.